The National Institutes of Health (NIH) is reportedly planning to launch a cancer vaccine development program. Moderna's experimental cancer therapy showed promising results in a recent clinical trial ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Moderna Inc MRNA shares are rising Friday to a fresh 52-week high. The stock enters the Nasdaq-100 Index. Here’s what you should know. Moderna’s shares are changing hands between $219.37 and $219.56 ...

Moderna’s audacious bet that it can transform cancer treatment with customized mRNA technology is getting closer to reality. The biotech company, already a household name for its mRNA COVID-19 vaccine ...

After a more than sevenfold YTD jump, Moderna (MRNA) fell nearly 10% in afternoon trading on Friday, becoming the biggest decliner in the S&P 500 (SP500) as investors await detailed results from a ...

SA Spotlight uses AI to summarize content published on Seeking Alpha. All summaries are reviewed by human editors prior to publication. Moderna (MRNA) shares surged just over 14% on Friday, ending at ...

Oct 22 (Reuters) - Moderna's shares sank over 25% on Thursday as late-stage trial data for its personalized melanoma vaccine, developed with Merck, triggered what analysts called a "sell-the-news" ...

Moderna stock has surged 658% year to date to $223.60, yet analyst consensus targets the stock at just $123, a 45% discount to current price. Moderna's cancer vaccine showed a 49% reduction in ...

Moderna shares gained 18% last week—finishing it at their highest level in more than four years—after the New York Times reported Friday that the National Institutes of Health is planning a ...

Investors turned away from Moderna in recent years as its blockbuster coronavirus vaccine saw declining demand. The company’s pipeline progress looks promising today, sparking fresh optimism among ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. After public school teacher Gary Keblish ...